March 19, 2020 / 12:13 PM / 20 days ago

BRIEF-Biondvax's CEO Comments On Impact Of Covid-19 Pandemic On The Company's Ongoing Phase 3 Clinical Trial

March 19 (Reuters) - BiondVax Pharmaceuticals Ltd:

* BIONDVAX’S CEO COMMENTS ON IMPACT OF COVID-19 PANDEMIC ON THE COMPANY’S ONGOING PHASE 3 CLINICAL TRIAL

* BIONDVAX PHARMACEUTICALS LTD - CORONAVIRUS PANDEMIC HAS NOT SIGNIFICANTLY IMPACTED PHASE 3 CLINICAL TRIAL

* BIONDVAX PHARMACEUTICALS LTD - MOST OF SWAB SAMPLES WE EXPECTED TO OBTAIN FROM PARTICIPANTS EXHIBITING FLU LIKE SYMPTOMS HAVE ALREADY BEEN COLLECTED

* BIONDVAX PHARMACEUTICALS LTD - CONTINUING TO COLLECT SWAB SAMPLES WHILE ADHERING TO RESTRICTIONS IMPOSED BY LOCAL AUTHORITIES

* BIONDVAX - AS LONG AS SITUATION DOES NOT SIGNIFICANTLY DETERIORATE, CRO & STATISTICIAN CURRENTLY EXPECT CO TO REACH TARGETED NUMBER OF SWAB SAMPLES

* BIONDVAX - WILL CONTINUE TO TAKE STEPS TO ENABLE CO TO PUBLISH RESULTS FROM M-001 UNIVERSAL INFLUENZA VACCINE CANDIDATE STUDY BY END OF YEAR Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below